Dossier assessment

Luspatercept (myelodysplastic syndromes) – Benefit assessment according to § 35a Social Code Book V

Report documents

Indication:

Adults with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS)

who have not yet received and who are eligible for erythropoiesis-stimulating agent-based therapy
without ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoiesis-stimulating agent-based therapy

Result of dossier assessment:

Patients:

who have not yet received and who are eligible for erythropoiesis-stimulating agent-based therapy: added benefit not proven
without ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoiesis-stimulating agent-based therapy: added benefit not proven

Project no.: A24-50
Commission: Commission awarded on 30.04.2024 by the Federal Joint Committee (GBA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Haematology
Note: After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
DOI: https://doi.org/10.60584/A24-50_en

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.